Intratumoral LAK cell and interleukin-2 therapy of human gliomas

D. Barba, S. C. Saris, C. Holder, S. A. Rosenberg, E. H. Oldfield

Research output: Contribution to journalArticle

Abstract

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) offers the possibility of a new treatment for patients with malignant glial tumors. In a clinical trial, the effectiveness of a 5-day treatment cycle of direct intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter system in patients with recurrent malignant gliomas was studied. Ten patients were entered into the study nine of whom were treated with 15 cycles of LAK cells (0.9 to 2.10 x 109 cells) and IL-2 (49 to 450 x 103 U/kg). The 10th patient in the study was not treated because of the onset of severe neurological deficits prior to beginning immunotherapy. Of the nine patients treated, one had a partial tumor response to immunotherapy as documented by computerized tomography. Neurological side effects occurred in all patients undergoing treatment and were related to increases in cerebral edema that appeared to be mediated by the immunotherapy. This report demonstrates the present limitations of regional adoptive immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalJournal of Neurosurgery
Volume70
Issue number2
StatePublished - 1989
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Glioma
Interleukin-2
Immunotherapy
Adoptive Immunotherapy
Neuroglia
Therapeutics
Neoplasms
Brain Edema
Catheters
Tomography
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Barba, D., Saris, S. C., Holder, C., Rosenberg, S. A., & Oldfield, E. H. (1989). Intratumoral LAK cell and interleukin-2 therapy of human gliomas. Journal of Neurosurgery, 70(2), 175-182.

Intratumoral LAK cell and interleukin-2 therapy of human gliomas. / Barba, D.; Saris, S. C.; Holder, C.; Rosenberg, S. A.; Oldfield, E. H.

In: Journal of Neurosurgery, Vol. 70, No. 2, 1989, p. 175-182.

Research output: Contribution to journalArticle

Barba, D, Saris, SC, Holder, C, Rosenberg, SA & Oldfield, EH 1989, 'Intratumoral LAK cell and interleukin-2 therapy of human gliomas', Journal of Neurosurgery, vol. 70, no. 2, pp. 175-182.
Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. Journal of Neurosurgery. 1989;70(2):175-182.
Barba, D. ; Saris, S. C. ; Holder, C. ; Rosenberg, S. A. ; Oldfield, E. H. / Intratumoral LAK cell and interleukin-2 therapy of human gliomas. In: Journal of Neurosurgery. 1989 ; Vol. 70, No. 2. pp. 175-182.
@article{5bb3f59944d84c218f56afef8283c779,
title = "Intratumoral LAK cell and interleukin-2 therapy of human gliomas",
abstract = "Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) offers the possibility of a new treatment for patients with malignant glial tumors. In a clinical trial, the effectiveness of a 5-day treatment cycle of direct intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter system in patients with recurrent malignant gliomas was studied. Ten patients were entered into the study nine of whom were treated with 15 cycles of LAK cells (0.9 to 2.10 x 109 cells) and IL-2 (49 to 450 x 103 U/kg). The 10th patient in the study was not treated because of the onset of severe neurological deficits prior to beginning immunotherapy. Of the nine patients treated, one had a partial tumor response to immunotherapy as documented by computerized tomography. Neurological side effects occurred in all patients undergoing treatment and were related to increases in cerebral edema that appeared to be mediated by the immunotherapy. This report demonstrates the present limitations of regional adoptive immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.",
author = "D. Barba and Saris, {S. C.} and C. Holder and Rosenberg, {S. A.} and Oldfield, {E. H.}",
year = "1989",
language = "English (US)",
volume = "70",
pages = "175--182",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - Intratumoral LAK cell and interleukin-2 therapy of human gliomas

AU - Barba, D.

AU - Saris, S. C.

AU - Holder, C.

AU - Rosenberg, S. A.

AU - Oldfield, E. H.

PY - 1989

Y1 - 1989

N2 - Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) offers the possibility of a new treatment for patients with malignant glial tumors. In a clinical trial, the effectiveness of a 5-day treatment cycle of direct intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter system in patients with recurrent malignant gliomas was studied. Ten patients were entered into the study nine of whom were treated with 15 cycles of LAK cells (0.9 to 2.10 x 109 cells) and IL-2 (49 to 450 x 103 U/kg). The 10th patient in the study was not treated because of the onset of severe neurological deficits prior to beginning immunotherapy. Of the nine patients treated, one had a partial tumor response to immunotherapy as documented by computerized tomography. Neurological side effects occurred in all patients undergoing treatment and were related to increases in cerebral edema that appeared to be mediated by the immunotherapy. This report demonstrates the present limitations of regional adoptive immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.

AB - Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) offers the possibility of a new treatment for patients with malignant glial tumors. In a clinical trial, the effectiveness of a 5-day treatment cycle of direct intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter system in patients with recurrent malignant gliomas was studied. Ten patients were entered into the study nine of whom were treated with 15 cycles of LAK cells (0.9 to 2.10 x 109 cells) and IL-2 (49 to 450 x 103 U/kg). The 10th patient in the study was not treated because of the onset of severe neurological deficits prior to beginning immunotherapy. Of the nine patients treated, one had a partial tumor response to immunotherapy as documented by computerized tomography. Neurological side effects occurred in all patients undergoing treatment and were related to increases in cerebral edema that appeared to be mediated by the immunotherapy. This report demonstrates the present limitations of regional adoptive immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.

UR - http://www.scopus.com/inward/record.url?scp=0024510754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024510754&partnerID=8YFLogxK

M3 - Article

C2 - 2643685

AN - SCOPUS:0024510754

VL - 70

SP - 175

EP - 182

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 2

ER -